{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T18:41:43Z","timestamp":1776192103044,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.ijantimicag.2023.106938","type":"journal-article","created":{"date-parts":[[2023,7,28]],"date-time":"2023-07-28T17:40:48Z","timestamp":1690566048000},"page":"106938","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates"],"prefix":"10.1016","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2742-1556","authenticated-orcid":false,"given":"Andrew","family":"Burke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4524-6229","authenticated-orcid":false,"given":"Robyn","family":"Carter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Tolson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Congdon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"Duplancic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2680-5803","authenticated-orcid":false,"given":"Evan","family":"Bursle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-7139","authenticated-orcid":false,"given":"Scott C.","family":"Bell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6218-435X","authenticated-orcid":false,"given":"Jason A.","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0686-171X","authenticated-orcid":false,"given":"Rachel","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2023.106938_bib0001","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3389\/fimmu.2020.00303","article-title":"The rise of non-tuberculosis mycobacterial lung disease","volume":"11","author":"Ratnatunga","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0002","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010\u20132014","volume":"15","author":"Adjemian","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0003","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/cid\/ciaa1125","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01879-19","article-title":"Dissecting erm [41]-mediated macrolide-inducible resistance in Mycobacterium abscessus","volume":"64","author":"Richard","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0005","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00798-2019","article-title":"Prognostic factors associated with long-term mortality in 1445 patients with nontuberculous mycobacterial pulmonary disease: a 15-year follow-up study","volume":"55","author":"Jhun","year":"2020","journal-title":"European Respir J"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0006","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01782-17","article-title":"Mycobacterium abscessus smooth and rough morphotypes form antimicrobial-tolerant biofilm phenotypes but are killed by acetic acid","volume":"62","author":"Clary","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0007","doi-asserted-by":"crossref","first-page":"3438","DOI":"10.1128\/JCM.02015-15","article-title":"Clonal diversification and changes in lipid traits and colony morphology in Mycobacterium abscessus clinical isolates","volume":"53","author":"Park","year":"2015","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0008","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1128\/JCM.01249-13","article-title":"Characterization of rough and smooth morphotypes of Mycobacterium abscessus isolates from clinical specimens","volume":"52","author":"Ruger","year":"2014","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0009","doi-asserted-by":"crossref","first-page":"8631563","DOI":"10.1155\/2019\/8631563","article-title":"An intensified regimen containing linezolid could improve treatment response in Mycobacterium abscessus lung disease","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0010","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40262-021-01010-4","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in the drug treatment of non-tuberculous mycobacteria in cystic fibrosis","volume":"60","author":"Burke","year":"2021","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 3","key":"10.1016\/j.ijantimicag.2023.106938_bib0011","doi-asserted-by":"crossref","first-page":"S327","DOI":"10.1093\/cid\/ciy625","article-title":"Linezolid-based regimens for multidrug-resistant tuberculosis (TB): a systematic review to establish or revise the current recommended dose for TB Treatment","volume":"67","author":"Bolhuis","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0012","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1128\/JCM.00274-17","article-title":"In vitro susceptibility testing of tedizolid against nontuberculous mycobacteria","volume":"55","author":"Brown-Elliott","year":"2017","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0013","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1093\/jac\/dkz511","article-title":"Is there a role for tedizolid in the treatment of non-tuberculous mycobacterial disease?","volume":"75","author":"Ruth","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0014","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00356-20","article-title":"Safety and tolerability of more than six days of tedizolid treatment","volume":"64","author":"Mensa Vendrell","year":"2020","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-beta-lactamase inhibitor combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0017","first-page":"379","article-title":"Impact of relebactam-mediated inhibition of Mycobacterium abscessus BlaMab \u03b2-lactamase on the in vitro and intracellular efficacy of imipenem","volume":"75","author":"Le Run","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0018","first-page":"e02623","article-title":"In vitro activity of the new beta-lactamase inhibitors relebactam and vaborbactam in combination with beta-lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0019","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/s41598-020-57844-8","article-title":"Effect of amoxicillin in combination with imipenem-relebactam against Mycobacterium abscessus","volume":"10","author":"Lopeman","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0020","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.tcsw.2021.100064","article-title":"In vitro efficacy of relebactam versus avibactam against Mycobacterium abscessus complex","volume":"7","author":"Harrison","year":"2021","journal-title":"Cell Surf"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0021","article-title":"In vitro effects of diazabicyclooctane \u03b2-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex","volume":"106669","author":"Misawa","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0023","doi-asserted-by":"crossref","first-page":"R46","DOI":"10.1186\/gb-2014-15-3-r46","article-title":"Kraken: ultrafast metagenomic sequence classification using exact alignments","volume":"15","author":"Wood","year":"2014","journal-title":"Genome Biol"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0024","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00098-20","article-title":"Insights into the l,d-transpeptidases and d,d-carboxypeptidase of mycobacterium abscessus: ceftaroline, imipenem, and novel diazabicyclooctane inhibitors","volume":"64","author":"Dousa","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2023.106938_bib0025","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2017-210927","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0026","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis: executive summary","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0027","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1128\/AAC.05354-11","article-title":"Pulmonary disposition of tedizolid following administration of once-daily oral 200-milligram tedizolid phosphate in healthy adult volunteers","volume":"56","author":"Housman","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0028","article-title":"Tedizolid activity against clinical mycobacterium abscessus complex isolates: an in vitro characterization study","volume":"2095","author":"Tang","year":"20189","journal-title":"Front Microbiol"},{"issue":"Suppl 2","key":"10.1016\/j.ijantimicag.2023.106938_bib0029","doi-asserted-by":"crossref","first-page":"S257","DOI":"10.1093\/infdis\/jiz475","article-title":"Glycopeptidolipid genotype correlates with the severity of mycobacterium abscessus lung disease","volume":"221","author":"Li","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0030","doi-asserted-by":"crossref","DOI":"10.1128\/spectrum.00571-22","article-title":"Molecular epidemiological characteristics of mycobacterium abscessus complex derived from non-cystic fibrosis patients in Japan and Taiwan","volume":"10","author":"Yoshida","year":"2022","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0031","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.diagmicrobio.2017.11.001","article-title":"In vitro activity of tedizolid against the Mycobacterium abscessus complex","volume":"90","author":"Compain","year":"2018","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0032","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.2147\/IDR.S362583","article-title":"In vitro susceptibility of nontuberculous mycobacteria to tedizolid","volume":"15","author":"Zhang","year":"2022","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.ijantimicag.2023.106938_bib0033","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ijid.2021.06.055","article-title":"Comparison of the in vitro activity of linezolid, tedizolid, sutezolid, and delpazolid against rapidly growing mycobacteria isolated in Beijing, China","volume":"109","author":"Wen","year":"2021","journal-title":"Int J Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857923002170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:45:34Z","timestamp":1760377534000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857923002170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0924857923002170"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106938","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro susceptibility testing of imipenem-relebactam and tedizolid against 102 Mycobacterium abscessus isolates","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106938","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"106938"}}